Mallinckrodt divests non-core point-of-care blood testing
This article was originally published in Clinica
Mallinckrodt is to sell its point-of-care blood testing equipment company, HemoCue, to a group of private equity funds, led by EQT Scandinavia BV, for an undisclosed amount. Mallinckrodt has three main product groups - respiratory, imaging and pharmaceuticals - and no longer considers its blood testing unit to be core business.
You may also be interested in...
Cilta-cel maintained high response rates in longer-term multiple myeloma data, but ide-cel causes less cytokine release syndrome and severe neurotoxicity – and it has a March decision date at the US FDA.
Our updated graphic tracker of key developments from the leading vaccine candidates.
Pathway open for drug as post-covalent BTK option as Loxo gears up for "risky" Phase III head-to-head study in Q1 2021.